Affiliations 

  • 1 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp
  • 2 Luis Diaz Laboratory, MSKCC, Sloan Kettering Institute, New York, USA
  • 3 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • 4 Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
  • 5 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 6 Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany
  • 7 Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
  • 8 Department of Medical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital, Mumbai, India
  • 9 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Seoul, Korea
  • 10 Department of Radiotherapy & Oncology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 11 Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
  • 12 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
  • 13 Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
  • 14 Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
  • 15 Oncology Unit, Faculty of Medicine, UiTM Sg Buloh, Selangor, Malaysia
  • 16 Division of Medical Oncology, Department of Internal Medicine, Cancer Research Institute, College of Medicine, St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
  • 17 Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
  • 18 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 19 Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy
  • 20 Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
  • 21 Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Center, Leipzig University Medical Center, Leipzig, Germany
  • 22 Department of Biostatistics, Yokohama City University, Kanagawa, Japan
  • 23 Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain
  • 24 Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • 25 CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
  • 26 Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • 27 Department of Clinical Oncology, Tohoku University School of Medicine, Sendai, Japan
  • 28 ESMO, Lugano, Switzerland
Ann Oncol, 2021 12;32(12):1496-1510.
PMID: 34411693 DOI: 10.1016/j.annonc.2021.08.1752

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications